Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 166 citing Ellenberg: Placebo-controlled trials and active-control trials in the evaluation of new treatment.... (0.07 sec) 

Placebo-controlled trials and active-control trials in the evaluation of new …

- annals.org
R Temple, SS Ellenberg - Annals of Internal Medicine, 2000 - Am Coll Physicians
In recent years, several authors have argued that placebo-controlled trials are invariably unethical
when known effective therapy is available for the condition being studied, regardless of the condition
or the consequences of deferring treatment. Some have also disputed the value of ...
Cited by 396 - Related articles - BL Direct - All 9 versions

Principal results of the controlled onset verapamil investigation of cardiovascular …

- zhaoys.com [PDF] 
HR Black, WJ Elliott, G Granditis, P Grambsch - ACC Current Journal Review, 2003 - Elsevier
Methods: A double-blind randomized trial in 16,602 subjects with hypertension and 1 or more
other CV risk factors. The primary end point was a myocardial infarction, stroke or CV death.
The study was designed to last 5 years. Equivalent effectiveness was pre-specified if the ...
Cited by 347 - Related articles - BL Direct - All 14 versions

[PDF] The pharmacological treatment of urinary incontinence


KE Andersson, R Appell, LD Cardozo, C Chapple, HP … - BJU international, 1999 - icsoffice.org
Page 1. Committee 10 Pharmacological Treatment of Urinary Incontinence Chairman KE
ANDERSSON (SWEDEN) Members R. APPELL (USA), L. CARDOZO (UK), C. CHAPPLE
(UK), H. DRUTZ (CANADA), J. FOURCROY, O. NISHIZAWA (JAPAN), ...
Cited by 238 - Related articles - BL Direct - All 9 versions

Lessons from the glitazones: a story of drug development


EAM Gale - The Lancet, 2001 - Elsevier
Troglitazone, the first in the thiazolidinedione class of oral hypoglycaemic agents, was launched
in the USA in March, 1997. It reached Europe later that year, only to be withdrawn within weeks
on the grounds of liver toxicity. Meanwhile it went on to generate sales of over $2 billion in ...
Cited by 176 - Related articles - BL Direct - All 5 versions

The ethics of placebo-controlled trials--a middle ground


EJ Emanuel, FG Miller - The New England journal of medicine, 2001 - nejm.highwire.org
The first placebo-controlled trial was probably conducted in 1931, when sanocrysin was compared
with distilled water for the treatment of tuberculosis. 1 Ever since then, placebo-controlled trials
have been controversial, especially when patients randomly assigned to receive placebo ...
Cited by 164 - Related articles - BL Direct - All 16 versions

[PDF] Non-inferiority trials: design concepts and issues-the encounters of academic …


RB D'Agostino, JM Massaro, LM Sullivan - Statistics in Medicine, 2002 - haberle.com
STATISTICS IN MEDICINE Statist. Med. 2003; 22:169–186 (DOI: 10.1002/sim.1425) ...
Non-inferiority trials: design concepts and issues – the encounters of academic consultants in
statistics ... Ralph B. D'Agostino Sr.1;2;∗;† , Joseph M. Massaro1;2;3 and Lisa M. ...
Cited by 131 - Related articles - View as HTML - BL Direct - All 8 versions

A dose-comparison trial of topiramate as monotherapy in recently diagnosed …


FG Gilliam, F Veloso, MAM Bomhof, SK Gazda, V Biton, … - Neurology, 2003 - AAN Enterprises
Methods: Adults and children ( 3 years of age) were eligible if the maximum interval since epilepsy
diagnosis was 3 years and patients had one to six partial-onset seizures during a 3-month retrospective
baseline. At study entry, patients (N = 252) were untreated or receiving one antiepileptic ...
Cited by 109 - Related articles - BL Direct - All 4 versions

Good enough: a primer on the analysis and interpretation of noninferiority trials

- annals.org [PDF] 
S Kaul, GA Diamond - Annals of internal medicine, 2006 - Am Coll Physicians
Active-control noninferiority trials are being performed with increas- ing frequency when standard
placebo-controlled trials are consid- ered unethical. Three attributes are optimally required to
establish noninferiority: 1) The treatment under consideration exhibits ther- apeutic ...
Cited by 97 - Related articles - BL Direct - All 6 versions

Ximelagatran compared with warfarin for prevention of thromboembolism in …


JL Halperin - American Heart Journal, 2003 - Elsevier
SPORTIF III is a randomized, open-label, parallel-group study with blinded event assessment
involving 3407 patients at 259 sites in 23 countries. SPORTIF V is similar, but with double-blind
treatment allocation involving 3922 patients at 409 North American sites. The primary end ...
Cited by 91 - Related articles - All 3 versions

[PDF] Design and analysis of non-inferiority mortality trials in oncology


M Rothmann, N Li, G Chen, GYH Chi, R Temple, HH … - Statistics in Medicine, 2002 - sctweb.org
STATISTICS IN MEDICINE Statist. Med. 2003; 22:239–264 (DOI: 10.1002/sim.1400) ... Design
and analysis of non-inferiority mortality trials in oncology ‡;¶ ... Mark Rothmann1;∗;† , Ning
Li1, Gang Chen1, George YH Chi1, Robert Temple2 and Hsiao-Hui Tsou1
Cited by 85 - Related articles - View as HTML - BL Direct - All 6 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google